ended
a
savings
are
project
nexium
the
health
think
drool
practically
ball
average
advantages
projections
over
purchasing
analysts
yeartodate
counted
thing
045
quite
still
correction
winning
growth
predict
known
who
facility
investor
give
nine
shares
positive
delay
wellness
benefit
confidence
results
through
begin
industry
even
also
wellplaced
timing
reasons
june
launch
lack
part
second
news
so
it
again
year
will
well
helpful
been
initiatives
large
companys
john
issues
change
past
than
to
which
market
dropped
stated
you
quarter
they
however
this
agreement
rise
aid
has
overrule
ranbaxy
matter
higher
retailer
difficult
rates
ceo
pricetoearningstogrowth
these
fiscal
company
everything
rite
arrangement
as
both
if
wont
away
simply
offset
peg
should
ratio
lowered
kind
here
bad
note
standley
lynch
around
anticipated
crystal
general
in
prove
decline
deal
weeks
seems
would
never
about
positives
make
generic
next
blockbuster
early
good
can
three
initial
problems
new
but
right
financial
fantastic
and
up
with
key
heartburn
might
impact
until
delayed
nice
drugs
have
polled
go
behind
drug
five
earnings
dilemma
significantly
due
thats
whole
yield
various
of
factor
succeeds
extent
including
pharmacy
thanks
20
resolve
his
network
peter
months
approval
for
could
on
eventually
came
announces
is
chains
mckesson
mount
although
stock
28
be
lower
or
fda
enough
that
reimbursement
generics
one
importance
underestimate
healths
availability
doing
more
cvs
expectations
january
august
build
nearterm
from
longterm
couple
level
benefits
when
legendary
earlier
longer
laboratorys
times
was
years
manufacturing
momentum
cause
important
goes
cover
thomson
precipitated
front
version
no
scrambling
cases
its
by
aids
run
time
